Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial
This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
Our study is seeking individuals aged 18-60, who have been diagnosed with a traumatic brain injury (TBI) to participate.
The study plans to learn more about the impacts of cannabidiol (CBD) on individuals with TBI. The 12-weeks of the study will involve using CBD or placebo.
Main Procedures Involved: -Blood draw -Questionnaires and cognitive tasks -Urine drug test
Duration of Participation: 12 weeks
18 to 60 years
-Between the ages of 18-60 -Diagnosed with a traumatic brain injury (TBI) -Interested in using cannabidiol (CBD) for TBI symptoms
Kent Hutchison, PhD
Protocol Number: 22-1427
More information available at ClinicalTrials.gov: NCT05632627
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers